CN115089711A - HIF-1α抑制剂在雄激素性脱发治疗中的应用 - Google Patents
HIF-1α抑制剂在雄激素性脱发治疗中的应用 Download PDFInfo
- Publication number
- CN115089711A CN115089711A CN202210465853.7A CN202210465853A CN115089711A CN 115089711 A CN115089711 A CN 115089711A CN 202210465853 A CN202210465853 A CN 202210465853A CN 115089711 A CN115089711 A CN 115089711A
- Authority
- CN
- China
- Prior art keywords
- hif
- androgenetic alopecia
- alpha
- hair
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 85
- 201000002996 androgenic alopecia Diseases 0.000 title claims abstract description 68
- 206010068168 androgenetic alopecia Diseases 0.000 title claims abstract description 66
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 title claims abstract 8
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 title claims abstract 8
- 238000011282 treatment Methods 0.000 title claims description 14
- 239000003112 inhibitor Substances 0.000 title description 15
- 230000014509 gene expression Effects 0.000 claims abstract description 24
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 20
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 claims abstract description 10
- CDJNNOJINJAXPV-UHFFFAOYSA-N 5-[1-[[2-(4-cyclopropylpiperazin-1-yl)pyridin-4-yl]methyl]-5-methylpyrazol-3-yl]-3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazole Chemical compound CC1=CC(C=2ON=C(N=2)C=2C=CC(OC(F)(F)F)=CC=2)=NN1CC(C=1)=CC=NC=1N(CC1)CCN1C1CC1 CDJNNOJINJAXPV-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 101150024413 NMUR1 gene Proteins 0.000 claims abstract description 9
- 101150035162 PRRX1 gene Proteins 0.000 claims abstract description 9
- 101150018417 VIM gene Proteins 0.000 claims abstract description 9
- 101150019088 TNFRSF1B gene Proteins 0.000 claims abstract description 7
- 210000004761 scalp Anatomy 0.000 claims description 16
- -1 Fbln1 Proteins 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 101150089908 Pcolce gene Proteins 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 101100281686 Mus musculus Fstl1 gene Proteins 0.000 claims description 2
- 238000013115 immunohistochemical detection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000010172 mouse model Methods 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 231100000360 alopecia Toxicity 0.000 abstract description 7
- 101150001032 FSTL1 gene Proteins 0.000 abstract description 6
- 230000003779 hair growth Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 44
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 44
- 102000001307 androgen receptors Human genes 0.000 description 38
- 108010080146 androgen receptors Proteins 0.000 description 38
- 210000004209 hair Anatomy 0.000 description 26
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 210000003780 hair follicle Anatomy 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 13
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 12
- 239000003098 androgen Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229960003604 testosterone Drugs 0.000 description 12
- 229960003473 androstanolone Drugs 0.000 description 10
- 230000003676 hair loss Effects 0.000 description 10
- 206010021143 Hypoxia Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000024963 hair loss Diseases 0.000 description 8
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 7
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 7
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 7
- 102000049939 Smad3 Human genes 0.000 description 7
- 102100023132 Transcription factor Jun Human genes 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001061 forehead Anatomy 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102100033875 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Human genes 0.000 description 3
- 101000640851 Homo sapiens 3-oxo-5-alpha-steroid 4-dehydrogenase 2 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 206010000029 5-alpha-reductase deficiency Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010069941 DNA receptor Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241001248531 Euchloe <genus> Species 0.000 description 1
- 230000010558 Gene Alterations Effects 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004919 hair shaft Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 210000005195 occipital scalp Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000004918 root sheath Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210465853.7A CN115089711A (zh) | 2022-04-29 | 2022-04-29 | HIF-1α抑制剂在雄激素性脱发治疗中的应用 |
| PCT/CN2023/090743 WO2023208013A1 (fr) | 2022-04-29 | 2023-04-26 | APPLICATION D'UN INHIBITEUR DE HIF-1α DANS LE TRAITEMENT DE L'ALOPÉCIE ANDROGÉNIQUE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210465853.7A CN115089711A (zh) | 2022-04-29 | 2022-04-29 | HIF-1α抑制剂在雄激素性脱发治疗中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115089711A true CN115089711A (zh) | 2022-09-23 |
Family
ID=83287626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210465853.7A Pending CN115089711A (zh) | 2022-04-29 | 2022-04-29 | HIF-1α抑制剂在雄激素性脱发治疗中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115089711A (fr) |
| WO (1) | WO2023208013A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023208013A1 (fr) * | 2022-04-29 | 2023-11-02 | 苏州翊鹏医药科技有限公司 | APPLICATION D'UN INHIBITEUR DE HIF-1α DANS LE TRAITEMENT DE L'ALOPÉCIE ANDROGÉNIQUE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2854243A1 (fr) * | 2003-04-24 | 2004-10-29 | Oreal | Procede de determination d'etats pre-alopeciques et/ou d'atteintes cutanees au moyen d'un marqueur predictif: hif-1(hypoxia inducible factor-1) |
| CN107429284A (zh) * | 2016-03-25 | 2017-12-01 | 花王株式会社 | 皮脂腺或毛囊选择性雄激素受体活性控制剂的评价或选择方法 |
| CN109069389A (zh) * | 2016-04-29 | 2018-12-21 | 宝洁公司 | 用n-羟基吡啶酮治疗毛发疾病的方法 |
| CN112587665A (zh) * | 2021-03-08 | 2021-04-02 | 苏州大学 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
| KR20210129565A (ko) * | 2020-04-20 | 2021-10-28 | 주식회사 뷰렌코리아 | 전립선 비대증 또는 안드로겐성 탈모증 예방, 개선 또는 치료용 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010075869A1 (fr) * | 2008-12-30 | 2010-07-08 | European Molecular Biology Laboratory (Embl) | Toluidine sulfonamides et leur utilisation |
| CN115089711A (zh) * | 2022-04-29 | 2022-09-23 | 苏州翊鹏医药科技有限公司 | HIF-1α抑制剂在雄激素性脱发治疗中的应用 |
-
2022
- 2022-04-29 CN CN202210465853.7A patent/CN115089711A/zh active Pending
-
2023
- 2023-04-26 WO PCT/CN2023/090743 patent/WO2023208013A1/fr unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2854243A1 (fr) * | 2003-04-24 | 2004-10-29 | Oreal | Procede de determination d'etats pre-alopeciques et/ou d'atteintes cutanees au moyen d'un marqueur predictif: hif-1(hypoxia inducible factor-1) |
| CN107429284A (zh) * | 2016-03-25 | 2017-12-01 | 花王株式会社 | 皮脂腺或毛囊选择性雄激素受体活性控制剂的评价或选择方法 |
| CN109069389A (zh) * | 2016-04-29 | 2018-12-21 | 宝洁公司 | 用n-羟基吡啶酮治疗毛发疾病的方法 |
| KR20210129565A (ko) * | 2020-04-20 | 2021-10-28 | 주식회사 뷰렌코리아 | 전립선 비대증 또는 안드로겐성 탈모증 예방, 개선 또는 치료용 조성물 |
| CN112587665A (zh) * | 2021-03-08 | 2021-04-02 | 苏州大学 | AR抑制剂和/或HIF-1α抑制剂在制备药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| 于天池 等: ""缺氧诱导因子1和缺氧诱导因子2抑制剂靶向治疗癌症的研究进展"", 《医学综述》, vol. 23, no. 7, pages 1305 - 1309 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023208013A1 (fr) * | 2022-04-29 | 2023-11-02 | 苏州翊鹏医药科技有限公司 | APPLICATION D'UN INHIBITEUR DE HIF-1α DANS LE TRAITEMENT DE L'ALOPÉCIE ANDROGÉNIQUE |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023208013A1 (fr) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Strazzulla et al. | Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis | |
| Pratt et al. | Alopecia areata | |
| Santos et al. | Drug discovery for alopecia: gone today, hair tomorrow | |
| Ellis et al. | Androgenetic alopecia: pathogenesis and potential for therapy | |
| Shorter et al. | Human hair follicles contain two forms of ATP‐sensitive potassium channels, only one of which is sensitive to minoxidil | |
| Milner et al. | Exogen, shedding phase of the hair growth cycle: characterization of a mouse model | |
| JP2002501366A (ja) | 心筋不全の診断と治療 | |
| WO2023208013A1 (fr) | APPLICATION D'UN INHIBITEUR DE HIF-1α DANS LE TRAITEMENT DE L'ALOPÉCIE ANDROGÉNIQUE | |
| Colding-Jørgensen et al. | Hair glucocorticoids are not a historical marker of stress–exploring the time-scale of corticosterone incorporation into hairs in a rat model | |
| Anastassakis et al. | Hormonal and genetic etiology of male androgenetic alopecia | |
| CN115721716B (zh) | Mdh2抑制剂在雄激素性脱发治疗中的应用 | |
| Tobin | The biogenesis and growth of human hair | |
| WO2020052629A1 (fr) | Application d'un ctpb activateur de p300 et d'un dérivé de celui-ci pour améliorer l'expression du collagène col17a1 | |
| CN110038116B (zh) | 人肝脏分泌蛋白gpnmb或其拮抗剂或激动剂的用途 | |
| He et al. | Amygdalin ameliorates alopecia areata on C3H/HeJ mice by inhibiting inflammation through JAK2/STAT3 pathway | |
| EP3302716B1 (fr) | Procédés d'identification d'agents cosmétiques dépendant du rythme circadien pour des compositions de soin de la peau | |
| WO2010051532A1 (fr) | Compositions et procédés concernant l’apnée obstructive du sommeil | |
| JP5697099B2 (ja) | 掻痒抑制剤 | |
| CN117257958A (zh) | Trps1抑制剂的新用途及用于治疗和/或预防雄激素性秃发的药物 | |
| JP2005304491A (ja) | 成長期毛包中で発現亢進する遺伝子群を指標とした皮膚の発毛・脱毛状態の予知方法、並びに育毛剤及び／又は除毛剤のスクリーニング方法 | |
| Alhaidari | An approach to disorders of pigmentation | |
| CN117482238A (zh) | TRPMLs通道激动剂在制备促进毛发生长的药物中的用途 | |
| Ahmed et al. | An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management | |
| US20190142722A1 (en) | Methods and compositions for promoting or inducing hair growth | |
| Yilmaz et al. | Prospects of integrated multi-omics-driven biomarkers for efficient hair loss therapy from systems biology perspective |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |